Routine

Chronic primary pain (persistent pain >3 months; chronic pain syndrome, incl. chronic widespread pain)

Pain / chronic disease · Geriatric & General
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Pain persisting or recurring for more than 3 months. Chronic primary pain has no clear underlying condition or is out of proportion to any identifiable injury/disease (e.g. fibromyalgia, chronic widespread pain, chronic primary low back pain); chronic secondary pain arises from an underlying condition (osteoarthritis, cancer, neuropathy). Management is biopsychosocial and self-management focused. Crucially, NICE advises AGAINST starting opioids, NSAIDs, paracetamol, benzodiazepines or gabapentinoids for chronic PRIMARY pain, as harms outweigh benefits; the emphasis is on exercise, psychological therapy, and (for primary pain) antidepressants may be considered.

Red flags

  • New or changing pain with systemic features (weight loss, fever, night pain) — exclude malignancy/infection
  • Neurological deficit, saddle anaesthesia, bladder/bowel dysfunction — cauda equina / cord compression
  • Escalating opioid use, aberrant drug-seeking, or signs of dependence/diversion
  • Severe depression or suicidal ideation associated with chronic pain
  • A missed treatable secondary cause being managed as 'primary' pain

Assessment

Differential diagnosis

  • Chronic primary pain: fibromyalgia, chronic widespread pain, chronic primary low back/pelvic pain, chronic primary headache
  • Chronic secondary pain (treat the cause): osteoarthritis/inflammatory arthritis, neuropathic (diabetic, post-herpetic, radicular), cancer pain, visceral (IBS, endometriosis), post-surgical
  • Central sensitisation; nociplastic pain
  • Comorbid depression, anxiety, sleep disturbance, catastrophising driving pain
  • Red-flag pathology masquerading as chronic pain (malignancy, infection, fracture, cauda equina)

Investigations

  • Thorough history and examination to classify primary vs secondary and exclude red flags; validated pain/impact and mood/sleep screens
  • Investigate only to exclude a treatable/serious underlying cause or where a specific secondary diagnosis is suspected — avoid repeated/unnecessary imaging and tests that reinforce illness focus
  • Assess function, psychosocial factors, beliefs, expectations and the impact on life/work
  • Screen for depression, anxiety, sleep disorder and substance/opioid dependence

Management

  • Build a therapeutic, collaborative relationship; validate the pain and explain the biopsychosocial model and realistic goals (function over cure)
  • Prioritise non-pharmacological, self-management approaches: supervised exercise/physical activity programmes (core, high-value), pacing
  • Offer psychological therapy: CBT or acceptance and commitment therapy (ACT) for chronic primary pain
  • Consider acupuncture for some chronic primary pain where available (per NICE)
  • For chronic PRIMARY pain, do NOT initiate paracetamol, NSAIDs, opioids, benzodiazepines or gabapentinoids — evidence shows little benefit and significant harm; antidepressants may be considered (even without depression)
  • For chronic SECONDARY pain, treat the underlying condition and use condition-appropriate analgesia (e.g. neuropathic agents for neuropathic pain, topical/oral analgesia for OA per its guideline)
  • Review existing analgesia and deprescribe harmful/ineffective long-term opioids and gabapentinoids with a supported taper
  • Address sleep, mood, work and social factors; signpost self-management and peer support; set regular review
  • Refer to multidisciplinary pain management programme for complex/refractory cases

Drugs & doses

Chronic PRIMARY pain (NICE NG193): do NOT start paracetamol, NSAIDs, opioids, benzodiazepines or gabapentinoids — explain harms outweigh benefits
Antidepressant for chronic primary pain (may be offered even without depression): amitriptyline 10-25 mg PO at night, or duloxetine 30-60 mg PO once daily (also first-line in fibromyalgia/neuropathic pain) [verify local dose]
Neuropathic (secondary) pain: amitriptyline, duloxetine, gabapentin or pregabalin (titrated) per NICE CG173 [verify local dose]
Osteoarthritis (secondary): topical NSAID first-line, then oral NSAID at lowest dose with PPI; avoid long-term opioids [verify local dose]
Deprescribe long-term opioids/gabapentinoids with a gradual taper (e.g. reduce by ~10% of dose every 1-4 weeks) and withdrawal support [verify local dose]

Disposition

Outpatient/primary care with structured review; refer to physiotherapy, pain psychology and multidisciplinary pain management programmes for complex cases. Urgent referral if red flags emerge.

Complications & pitfalls

  • Iatrogenic opioid/gabapentinoid dependence, misuse and overdose; drug side effects without benefit
  • Deconditioning, disability, work loss and social isolation
  • Depression, anxiety, sleep disturbance and reduced quality of life
  • Medicalisation and repeated low-value investigation reinforcing illness behaviour

Exam pearls

  • Guidance: NICE NG193 (chronic pain) — the landmark message is NOT to start common analgesics (incl. opioids and gabapentinoids) for chronic primary pain; offer exercise, psychological therapy, acupuncture, and consider an antidepressant.
  • Function and quality of life, not a pain score of zero, are the realistic goals.
  • Supervised exercise and CBT/ACT are high-value, evidence-based core treatments.
  • Distinguish primary from secondary pain — secondary pain is treated via its underlying condition's pathway.
  • Deprescribe long-term opioids and gabapentinoids that are not helping, with a planned taper and support — chasing higher doses harms patients.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.